| Jeffrey Alan Zuckerman, MD | |
|
596 Calle Cesar Gonzalez Apt 1822, San Juan, PR 00918-4358 | |
| (907) 388-1003 | |
| (907) 802-6625 |
| Full Name | Jeffrey Alan Zuckerman |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 35 Years |
| Location | 596 Calle Cesar Gonzalez Apt 1822, San Juan, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326153701 | NPI | - | NPPES |
| MD2954 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 2954 (Alaska) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 022848 (Puerto Rico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Presbyterian Hospital | Albuquerque, NM | Hospital |
| Prosser Memorial Hospital | Prosser, WA | Hospital |
| Riverside University Health System-medical Center | Moreno valley, CA | Hospital |
| Mclaren Northern Michigan | Petoskey, MI | Hospital |
| Bayhealth Hospital, Kent Campus | Dover, DE | Hospital |
| Entity Name | Solorad Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497137905 PECOS PAC ID: 1254645591 Enrollment ID: O20150731014377 |
News Archive
A new report has looked at all of England's swine flu deaths in children under 18 during the 2009 pandemic. Researchers found that there was a higher risk of dying from the influenza A H1N1 strain of flu among certain groups of children, such as those with pre-existing conditions and those of a Pakistani or Bangladeshi background. However it was unclear why.
Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.
PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.
AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.
› Verified 3 days ago
| Entity Name | 1st Choice Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306390232 PECOS PAC ID: 4880975341 Enrollment ID: O20170705003034 |
News Archive
A new report has looked at all of England's swine flu deaths in children under 18 during the 2009 pandemic. Researchers found that there was a higher risk of dying from the influenza A H1N1 strain of flu among certain groups of children, such as those with pre-existing conditions and those of a Pakistani or Bangladeshi background. However it was unclear why.
Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.
PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.
AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.
› Verified 3 days ago
| Entity Name | Fairbanks Ultrasound, Llc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235455809 PECOS PAC ID: 3577745264 Enrollment ID: O20170706001834 |
News Archive
A new report has looked at all of England's swine flu deaths in children under 18 during the 2009 pandemic. Researchers found that there was a higher risk of dying from the influenza A H1N1 strain of flu among certain groups of children, such as those with pre-existing conditions and those of a Pakistani or Bangladeshi background. However it was unclear why.
Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.
PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.
AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.
› Verified 3 days ago
| Entity Name | Pco Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881230563 PECOS PAC ID: 5395179329 Enrollment ID: O20220527000966 |
News Archive
A new report has looked at all of England's swine flu deaths in children under 18 during the 2009 pandemic. Researchers found that there was a higher risk of dying from the influenza A H1N1 strain of flu among certain groups of children, such as those with pre-existing conditions and those of a Pakistani or Bangladeshi background. However it was unclear why.
Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.
PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.
AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.
› Verified 3 days ago
| Entity Name | On-line Radiology Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710158498 PECOS PAC ID: 0648311548 Enrollment ID: O20220831000099 |
News Archive
A new report has looked at all of England's swine flu deaths in children under 18 during the 2009 pandemic. Researchers found that there was a higher risk of dying from the influenza A H1N1 strain of flu among certain groups of children, such as those with pre-existing conditions and those of a Pakistani or Bangladeshi background. However it was unclear why.
Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.
PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.
AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey Alan Zuckerman, MD 151 Calle De San Francisco, Ste 200, Pmb 1036, San Juan, PR 00901 Ph: (907) 388-1003 | Jeffrey Alan Zuckerman, MD 596 Calle Cesar Gonzalez Apt 1822, San Juan, PR 00918-4358 Ph: (907) 388-1003 |
News Archive
A new report has looked at all of England's swine flu deaths in children under 18 during the 2009 pandemic. Researchers found that there was a higher risk of dying from the influenza A H1N1 strain of flu among certain groups of children, such as those with pre-existing conditions and those of a Pakistani or Bangladeshi background. However it was unclear why.
Millennium: The Takeda Oncology Company today reported on data from oral presentations of VELCADE® (bortezomib) for Injection based therapy in multiple myeloma presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). These data highlight VELCADE based therapy in both transplant and non-transplant eligible previously untreated multiple myeloma patients, as well as VELCADE used as induction and/or maintenance therapy.
PROLOR Biotech, Inc.,, today reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.
AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey, focused on the development and commercialization of new therapies for abnormal levels of lipids in the blood, referred to as dyslipidemia.
Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.
› Verified 3 days ago
Bernardo Jose Marques Diaz, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 310 Lomas Verdes Ave. Suite 208, San Juan, PR 00927 Phone: 787-751-3150 Fax: 787-767-0338 | |
Dr. Roberto F Marchan, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 271 Ave J T Pinero, San Juan, PR 00927 Phone: 787-759-9660 Fax: 787-759-9660 | |
Wilmarie Rivera Hernandez, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 617 Calle Manuel Pavia, San Juan, PR 00909 Phone: 787-625-1446 | |
Dr. Wilma Rodriguez Mojica, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: Fernandez Street No. 6 , Third Floor, San Juan, PR 00918 Phone: 787-763-6336 Fax: 787-763-6207 | |
Luis Garcia Paredes, Radiology Medicare: Accepting Medicare Assignments Practice Location: 1462 Calle Prof Augusto Rodriguez, San Juan, PR 00909 Phone: 787-641-1616 | |
Mr. Roberto J Sein, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Ave De Diego 201, Plaza San Fco Ofic #30, San Juan, PR 00927 Phone: 787-751-5587 Fax: 787-753-4631 | |
Dr. Ivonne Marquez Valencia, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 258 Calle San Jorge, San Juan, PR 00912 Phone: 787-727-1000 |